Challenges in assessing costs of rheumatoid arthritis

Case Manager

Volumn 14, Issue 5, 2003, Pages 65-72

  Harrison, Melanie J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ARTICLE; DISEASE COURSE; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; JOINT PROSTHESIS; LIVER TOXICITY; MEDICAL ASSESSMENT; MEDICAL PRACTICE; PHYSICAL DISABILITY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE MANAGEMENT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG MONITORING; HEALTH CARE COSTS; HUMANS; MASS SCREENING; NEEDS ASSESSMENT; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 0242270720     PISSN: 10619259     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcm.2003.86     Document Type: Article

References (69)

1. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41:1998;778-799.
2. Emery P., Breedveld F.C., Dougados M., et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence-based development of a clinical guide. Ann Rheum Dis. 61:2002;290-297.
3. Yelin E., Meenan R., Nevitt M., Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med. 934:1980;551-556.
4. Massardo L., Gabriel S.E., Crowson C.S., et al. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol. 291:2002;52-56.
5. Blumberg S.N., Fox D.A. Rheumatoid arthritis: guidelines for emerging therapies. Am J Manag Care. 76:2001;617-626.
6. Erkan D., Yazici Y., Fields T., et al. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum. 47:2002;285-290.
7. Mikuls TR, O'Dell JR. Rheumatoid arthritis practice pattern variation [abstract 1321]. Presented at 64th Annual Scientific Meeting of the American College of Rheumatology and the 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, October 28-November 2, 2000, Philadelphia, Pa.
8. Pincus T., O'Dell J.R., Kremer J.M. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 13110:1999;768-774.
9. Spencer-Green G., Spencer-Green E. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis:how physicians manage treatment failures. J Rheumatol. 2511:1998;2088-2093.
10. van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med. 124:1996;699-707.
11. Ms̈tts̈nen T., Hannonen P., Leirisalo-Repo M. For the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 353:1999;1568-1573.
12. Mikuls T., Moreland L. The treatment of rheumatoid arthritis: a review of recent clinical trials. Curr Rheumatol Rep. 12:1999;135-138.
13. Erkan D, Yazici Y, Harrison MJ, Paget SA. Treatment preferences for early rheumatoid arthritis patients: how aggressive are rheumatologists? [abstract OP0118]. Presented at European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic.
14. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 462:2002;328-346.
15. Fuchs H.A., Kaye J.J., Callahan L.F., et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 16:1989;585-591.
16. Clarke A.E., St-Pierre Y., Joseph L., et al. Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs. J Rheumatol. 2811:2001;2416-2424.
17. Fries J.F., Williams C.A., Morfeld D., et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 39:1996;616-622.
18. Stenger A.A., Van Leeuwen M.A., Houtman P.M., et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol. 3711:1998;1157-1163.
19. Lubeck D.P., Katz P., Yelin E., et al. Long-term impact of etanercept (Enbrel) on health-related quality of life and functional status of persons with rheumatoid arthritis [abstract]. Arthritis Rheum. 44:(Suppl 9):2001;S184.
20. Fleischmann R, Baumgartner S, Moreland L, et al. Improvement of disability in RA patients with early vs established disease after treatment with Enbrel (etanercept) [abstract FRI0081]. Presented at European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic.
21. Gerloni V., Pontikaki I., Desiati F., et al. Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile chronic arthritis after one year treatment with monoctonal anti-tumor necrosis factor: a antibody (infliximab) [abstract]. Arthritis Rheum. 44:(Suppl 9):2001;S80.
22. Strand V., Tugwell P., Bombardier C., et al. Function and health-related quality of life: results from a randomized controlled trial of lefiunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 429:1999;1870-1878.
23. Schiff M.H., Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 303:2000;196-208.
24. Sule S., Bathon J.M. Disease-modifying effects of new rheumatoid arthritis therapies. Resid Staff Physician. 477:2001;15-28.
25. Erkan D., Yazici Y., Fields T., et al. 2000 vs 2001: is there any change in rheumatologists' optimal choice of first-line rheumatoid arthritis (RA) therapy? [abstract]. Arthritis Rheum. 44:(Suppl 9):2001;S320.
26. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol. 15:(Suppl 17):1997;S75-S81.
27. Buchbinder R., Hall S., Sambrook P.N., et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 20:1993;639-644.
28. Pincus T., Marcum S.B., Callahan L.F. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 19:1992;1885-1894.
29. Nuijten M.J., Engelfriet P., Duijn K., et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics. 1910:2001;1051-1064.
30. Malone DC. Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis [abstract]. Presented at 65th Annual Scientific Meeting of the American College of Rheumatology and the 36th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, November 11-16, 2001, San Francisco, Calif.
31. Enbrel [package insert]. Seattle: Immunex Corporation; 2002.
32. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1306:1999;478-486.
33. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med. 2001;344:76 and N Engl J Med 2001;344:240]. N Engl J Med 2000;343:1586-93.
34. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 354:1999;1932-1939.
35. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 343:2000;1594-1602.
36. Remicade [package insert]. Malvern (PA): Centocor; 2002.
37. Bresnihan B., Alvaro-Gracia J.M., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 4112:1998;2196-2204.
38. Bresnihan B, Newmark RD, Robbins S, et al. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis [abstract FRI0063]. Presented at European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic.
39. Miller DM, Ng E, Schiff MH, et al. Durability and rapidity of response for rheumatoid arthritis patients receiving therapy with anakinra (IL-1RA) [abstract FRI0077]. Presented at European League Against Rheumatism (EULAR)/European Congress of Rheumatology, June 13-16, 2001, Prague, Czech Republic.
40. Merkesdal S., Ruof J., Huelsemann J.L., et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol. 283:2001;657-661.
41. Ruof J., Hulsemann J.L., Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol. 112:1999;104-109.
42. Gabriel S.E., Tugwell P., O'Brien B., et al. Report of the OMERACT task force on economic evaluation. J Rheumatol. 26:1999;203-206.
43. Gabriel S.E., Crowson C.S., Luthra H.S., et al. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol. 26:1999;1269-1274.
44. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol. 23:(Suppl 44):1996;47-51.
45. Pugner K.M., Scott D.L., Holmes J.W., Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 295:(Suppl 9):2000;305-320.
46. Yelin E., Wanke L.A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 426:1999;1209-1218.
47. Newhall-Perry K., Law N.J., Ramos B., et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol. 275:2000;1156-1163.
48. Merkesdal S., Ruof J., Bernitt K., et al. Indirect medical costs of rheumatoid arthritis: development within the first three years after onset [abstract]. Arthritis Rheum. 41:1998;S225.
49. Criswell L.A., Such C.L. Cost effectiveness analysis of drug therapies for rheumatoid arthritis. J Rheumatol. 23:(Suppl 44):1996;52-55.
50. Birnbaum H.G., Barton M., Greenberg P.E., et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med. 42:2000;588-596.
51. Korthals-de-Bos IBC. Randomised comparison of step-down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis: indirect costs [abstract]. Presented at Annual Meeting of the International Society of Technology Assessment in Health Care, 1999, Edinburgh, Scotland.
52. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis [abstract 465]. Presented at 64th Annual Scientific Meeting of the American College of Rheumatology and the 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, October 28-November 2, 2000, Philadelphia, Pa.
53. Kavanaugh A., Lipsky P., Furst D., et al. Infliximab improves long-term quality of life and functional status in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 43:(Suppl 9):2000;S147.
54. Brennan A, Bansback N, Conway P, Reynolds AV. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK [abstract]. Presented at 65th Annual Scientific Meeting of the American College of Rheumatology and the 36th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, November 11-16, 2001, San Francisco, Calif.
55. Kavanaugh A., Heudebert G., Cush J., Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum. 25:1996;297-397.
56. McCabe C.J., Akehurst R.L., Kirsch J., et al. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK. Pharmacoeconomics. 142:1998;191-199.
57. Wolfe F, Flowers N, Burke T, et al. Increase in lifetime adverse drug reactions and increased disease severity among patients who will start Cox-2 agents: quantitative assessment of confounding by indication in 6,689 RA and OA patients [abstract 951]. Presented at 64th Annual Scientific Meeting of the American College of Rheumatology and the 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, October 28-November 2, 2000, Philadelphia, Pa.
58. Wolfe F, Pincus T. Poor outcome and non-response to DMARD therapy: a study of 6870 rheumatoid arthritis patients [abstract 695]. Presented at 64th Annual Scientific Meeting of the American College of Rheumatology and the 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, October 28-November 2, 2000, Philadelphia, Pa.
59. Krishnan E, Fries JF. Time trends in cumulative disability in rheumatoid arthritis 1960-1998 [abstract]. Presented at 65th Annual Scientific Meeting of the American College of Rheumatology and the 36th Annual Scientific Meeting of the Association of Rheumatology Health Professionals, November 11-16, 2001, San Francisco, Calif.
60. Jones K.W., Patel S.R. A family physician's guide to monitoring methotrexate. Am Fam Physician. 627:2000;1607-1614.
61. Prashker M.J., Meenan R.F. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum. 38:1995;318-325.
62. HealthCentral. PPD skin test. Available at: www.healthcentral.com/mhc/ top/OO3839.cfm#Cost . Cited 2002 Jan 14.
63. Coyle D., Welch V., Shea B., et al. Issues of consensus and debate for economic evaluation in rheumatology. J Rheumatol. 283:2001;642-647.
64. Lambert C.M., Hurst N.P., Forbes J.F., et al. Is day care equivalent in inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. Br Med J. 316:1998;965-969.
65. van Vollenhoven R.F., Gullstrom E., Brannemark S., Klareskog L. Dose escalation of infliximab in clinical practice: data from the Stockholm TNF registry [abstract]. Arthritis Rheum. 44:(Suppl 9):2001;S82.
66. Gallup E. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting. Manag Care Interface. 2001;14:52-4,57-8,69.
67. Solomon D.H., Bates D.W., Panush R.S., Katz J.N. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards. Ann Intern Med. 127:1997;52-60.
68. Young A., Dixey J., Kulinskaya E., et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 614:2002;335-340.
69. Gabriel S.E., Crowson C.S., Campion M.E., O'Fallon W.M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 24:1997;43-48.